{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:03:07Z","timestamp":1791370987499,"version":"4.3.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/FST\/LS-II\/2018\/210"],"award-info":[{"award-number":["SR\/FST\/LS-II\/2018\/210"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001427","name":"All India Council for Technical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["11013_33_2021-GIA HR"],"award-info":[{"award-number":["11013_33_2021-GIA HR"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4-4\/3\/MH\/2022-NCD-II"],"award-info":[{"award-number":["5\/4-4\/3\/MH\/2022-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejmech.2024.116563","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T22:18:41Z","timestamp":1717280321000},"page":"116563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Derivatives of D(\u2212) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-I: Synthesis, biological screening and in silico binding interaction analysis"],"prefix":"10.1016","volume":"274","author":[{"given":"Sanjib","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambati","family":"Himaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvankar","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip Kumar","family":"Baidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asit Kumar","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shovanlal","family":"Gayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaram","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-738X","authenticated-orcid":false,"given":"Tarun","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116563_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J. Blood Med."},{"key":"10.1016\/j.ejmech.2024.116563_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib4","series-title":"Pediatric Cancer Genetics","first-page":"47","article-title":"Genetic testing techniques","author":"Gomes","year":"2018"},{"key":"10.1016\/j.ejmech.2024.116563_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116563_bib6","doi-asserted-by":"crossref","first-page":"E186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116563_bib8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12325-022-02398-6","article-title":"The economic burden of chronic myeloid leukemia in patients with later lines: findings from a real-world analysis in Italy","volume":"40","author":"Breccia","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2024.116563_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116563_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European leukemianet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116563_bib11","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","article-title":"First-Line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI","volume":"59","author":"Saglio","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2024.116563_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-9966-33-15","article-title":"Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective","volume":"33","author":"Eckstein","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib13","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.21873\/anticanres.14215","article-title":"ABL1-directed inhibitors for CML: efficacy, resistance and future perspectives","volume":"40","author":"Massimino","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib14","article-title":"Chronic myeloid leukemia kinase domain mutations: a retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII hospital, Kwazulu-Natal, South Africa, Health","volume":"6","author":"Benjamin","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116563_bib15","first-page":"262","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct","volume":"8","author":"Shyam","year":"2023","journal-title":"Target Ther."},{"key":"10.1016\/j.ejmech.2024.116563_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1218821","article-title":"Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia","volume":"13","author":"Hu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116563_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113623","article-title":"Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies","volume":"223","author":"Das","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116563_bib18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/cells9051076","article-title":"Structure and function of human matrix metalloproteinases","volume":"9","author":"Laronha","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2024.116563_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.02.005","article-title":"Biochemical and biological attributes of matrix metalloproteinases","volume":"147","author":"Cui","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2024.116563_bib20","first-page":"339","article-title":"Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications","volume":"17","author":"Giannelli","year":"2002","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ejmech.2024.116563_bib21","first-page":"37","article-title":"Gelatinase-mediated migration and invasion of cancer cells","volume":"1755","author":"Bj\u00f6rklund","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2024.116563_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","article-title":"Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116563_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.critrevonc.2019.02.010","article-title":"Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer","volume":"137","author":"Gonzalez-Avila","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","article-title":"Role of matrix metalloproteinases in angiogenesis and cancer","volume":"9","author":"Quintero-Fabi\u00e1n","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116563_bib25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3389\/fimmu.2019.01278","article-title":"Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases","volume":"10","author":"Fields","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2024.116563_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131512","article-title":"Synthesis, biological activity, structure activity relationship study and liposomal formulation development of some arylsulfonyl pyroglutamic acid derivatives","volume":"1248","author":"Das","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2024.116563_bib27","first-page":"402","article-title":"Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells","volume":"105","author":"Janowska-Wieczorek","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib28","first-page":"4395","article-title":"Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML","volume":"19","author":"Kuittinen","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.2001.03160.x","article-title":"Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures","volume":"115","author":"Marquez-Curtis","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0145-2126(00)00104-1","article-title":"MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL)","volume":"25","author":"Kuittinen","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1365-2141.2002.03510.x","article-title":"Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia","volume":"117","author":"Lin","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2003.09.001","article-title":"The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia","volume":"50","author":"Klein","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib33","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2006-02-005363","article-title":"Cell-Surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression","volume":"108","author":"Stefanidakis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116563_bib34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.leukres.2007.01.015","article-title":"Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement","volume":"31","author":"Suminoe","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-0609.2009.01382.x","article-title":"Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation","volume":"83","author":"Reikvam","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2024.116563_bib36","first-page":"1083","article-title":"The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells, Leuk","volume":"34","author":"Wang","year":"2010","journal-title":"Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2009.07.039","article-title":"In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia","volume":"34","author":"Schneider","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib38","first-page":"640","article-title":"Expression and clinical significance of MMP-2 and MMP-9 in B acute lymphoblastic leukemia","volume":"22","author":"Pan","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.ejmech.2024.116563_bib39","first-page":"3043","article-title":"Pleiotropic roles of metalloproteinases in hematological malignancies: an update","volume":"17","author":"Chaudhary","year":"2016","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.ejmech.2024.116563_bib40","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10555-019-09828-y","article-title":"Pathological and therapeutic aspects of matrix metalloproteinases: implications in childhood leukemia","volume":"38","author":"Hsiao","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2024.116563_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/1062936X.2021.1955414","volume":"32","author":"Das","year":"2021","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/1062936X.2022.2041722","article-title":"Insight into the structural requirements of gelatinases (MMP-2 and MMP-9) inhibitors by multiple validated molecular modelling approaches: Part II","volume":"33","author":"Das","year":"2022","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib43","doi-asserted-by":"crossref","first-page":"21843","DOI":"10.1021\/acsomega.1c03628","article-title":"Hydroxamic acid derivatives: from synthetic strategies to medicinal chemistry applications","volume":"6","author":"Citarella","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116563_bib44","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.3390\/ijms21134747","article-title":"In vitro assessment of the genotoxic hazard of novel hydroxamic acid- and benzamide-type histone deacetylase inhibitors (HDACI)","volume":"21","author":"Friedrich","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116563_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not be the best histone deacetylase inhibitors--what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116563_bib46","doi-asserted-by":"crossref","first-page":"72373","DOI":"10.1039\/C5RA12606A","article-title":"Design of dual MMP-2\/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity","volume":"5","author":"Halder","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2024.116563_bib47","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1016\/j.bmc.2016.07.023","article-title":"Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico\/fragment-based lead identification and de novo lead modification: Syntheses and biological assays","volume":"24","author":"Adhikari","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116563_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2017.09.052","article-title":"A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line","volume":"141","author":"Mukherjee","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116563_bib49","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4155\/fmc-2018-0361","article-title":"Synthesis, anticancer activity, structure-activity relationship and binding mode of interaction studies of substituted pentanoic acids","volume":"11","author":"Dutta","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116563_bib50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4155\/fmc-2021-0049","article-title":"Synthesis, anticancer activity, SAR and binding mode of interaction studies of substituted pentanoic acids: Part II","volume":"14","author":"Datta","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116563_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.matpr.2023.10.158","article-title":"In-house glutamine based compound loaded poly-(D-L-lactide-coglycolide) nanoparticles as a possible candidate for the management of chronic myeloid leukemia","author":"Das","year":"2023","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.ejmech.2024.116563_bib52","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1021\/acs.organomet.2c00290","article-title":"Impact of biphenyl benzhydrazone-incorporated arene Ru (II) complexes on cytotoxicity and the cancer cell death mechanism","volume":"41","author":"Arunachalam","year":"2022","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2024.116563_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12659\/MSMBR.893327","article-title":"Dual AO\/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry","volume":"21","author":"Liu","year":"2015","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jmi.12133","article-title":"Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques","volume":"255","author":"Atale","year":"2014","journal-title":"J. Microsc."},{"key":"10.1016\/j.ejmech.2024.116563_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10495-022-01735-y","article-title":"Programmed cell death detection methods: a systematic review and a categorical comparison","volume":"27","author":"Kari","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejmech.2024.116563_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087223","article-title":"Molecular mechanisms of exopolysaccharide from aphanothece halaphytica (EPSAH) induced apoptosis in HeLa cells","volume":"9","author":"Ou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116563_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/486419","article-title":"Antigenotoxic and apoptotic activity of green tea polyphenol extracts on hexavalent chromium-induced DNA damage in peripheral blood of CD-1 mice: analysis with differential acridine orange\/ethidium bromide staining","volume":"2013","author":"Garc\u00eda-Rodr\u00edguez","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116563_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/1735-5362.305186","article-title":"Prodigiosin induced the caspase-dependent apoptosis in human chronic myelogenous leukemia","volume":"16","author":"Niakani","year":"2020","journal-title":"K562 cell. Res. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2024.116563_bib59","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/IJN.S231062","article-title":"Synthesis, characterization, biomedical application, molecular dynamic simulation and molecular docking of schiff base complex of Cu (II) supported on Fe3O4\/Sio2\/APTS","volume":"15","author":"Eshaghi Malekshah","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2024.116563_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67289-8","article-title":"Angiogenesis analyzer for ImageJ \u2014 a comparative morphometric analysis of \u201cendothelial tube formation assay\u201d and \u201cfibrin bead assay\u201d","volume":"10","author":"Carpentier","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116563_bib61","series-title":"Schrodinger Suite. Schrodinger","year":"2019"},{"key":"10.1016\/j.ejmech.2024.116563_bib62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/1062936X.2023.2209737","article-title":"Exploration of structural alerts and fingerprints for novel anticancer therapeutics: a robust classification-QSAR dependent structural analysis of drug-like MMP-9 inhibitors","volume":"34","author":"Baidya","year":"2023","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2021.111962","article-title":"Facile green synthesis of non-genotoxic, non-hemolytic organometallic silver nanoparticles using extract of crushed, wasted, and spent humulus lupulus (Hops): characterization, anti-bacterial, and anti-cancer studies","volume":"204","author":"Das","year":"2022","journal-title":"Environ. Res."},{"key":"10.1016\/j.ejmech.2024.116563_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2567.2007.02728.x","article-title":"Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages","volume":"124","author":"Oviedo-Orta","year":"2008","journal-title":"Immunol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T23:02:16Z","timestamp":1732143736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":63,"alternative-id":["S0223523424004434"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116563","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Derivatives of D(\u2212) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-I: Synthesis, biological screening and in silico binding interaction analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116563"}}